CDC Narrows RSV Vaccine Guidelines Due to Safety Concerns
The U.S. Centers for Disease Control and Prevention (CDC) has recently narrowed its original recommendations for the respiratory syncytial virus (RSV) vaccine, citing concerns over the risk of a side effect that can lead to paralysis or death. The recommendations originally stated adults over the age of 60 should receive the vaccine, but updates in […]
Guillain-Barré Syndrome ‘More Common Than Expected’ in Early RSV Vaccine Trial
Reports of the nervous system disorder Guillain-Barré syndrome (GBS) were “more common than expected” in the older adult population who received the new vaccine for respiratory syncytial virus (RSV). The data, reported by the U.S. Centers for Disease Control and Prevention (CDC), matched trial data reported earlier this year.1 GBS is a “polio-like” inflammatory autoimmune […]
New Study Documents COVID-19 Vaccine Harms—Low Platelets, GBS, Myocarditis
There’s a new paper out now in the journal Vaccine, and it’s about the COVID-19 vaccine and some of the harms due to the vaccine. It’s the largest observational analysis of 99 million people, and it’s entitled “COVID-19 Vaccines and Adverse Events of Special Interest: A Multinational Global Vaccine Data Network Cohort Study of 99 […]
Unknown Risks of COVID Shot Harm Revealed in New Report
At the request of the Health Resources Services Administration (HRSA), an agency in the U.S. Department of Health and Human Services (DHHS), the National Academies of Science, Engineering and Medicine assembled a committee of physicians and scientists to conduct a review of the evidence that COVID-19 shots can cause serious harm to health. The evidence […]
CDC Pushes Pfizer’s Pentavalent Meningococcal Vaccine
On Oct. 20, 2023, Pfizer, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its new pentavalent meningococcal vaccine, Penbraya, which targets five meningococcal serogroups (A, B, C, W and Y) that most commonly cause meningococcal disease in adolescents and young adults 10-25 years old. Penbraya, is recommended to be given in two […]
RSV Vaccines for Senior Adults Linked to Guillain-Barré Syndrome
On Feb. 29, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) presented a preliminary analysis that showed that 23 adults over the age of 65 who received a respiratory syncytial virus (RSV) vaccine developed Guillain-Barré syndrome (GBS).1 When a person develops GBS, including after an infection or […]
